BiotechTube

SPIKEVAX (mRNA-1273)

PreclinicalCompleted
0 views this week 0 watching
0
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

SARS-CoV-2, COVID-19

Conditions

SARS-CoV-2, COVID-19

Trial Timeline

Dec 18, 2020 → Nov 17, 2023

NCT ID
NCT05933304

About SPIKEVAX (mRNA-1273)

SPIKEVAX (mRNA-1273) is a preclinical stage product being developed by Moderna for SARS-CoV-2, COVID-19. The current trial status is completed. This product is registered under clinical trial identifier NCT05933304. Target conditions include SARS-CoV-2, COVID-19.

What happened to similar drugs?

4 of 20 similar drugs in SARS-CoV-2, COVID-19 were approved

Approved (4) Terminated (1) Active (16)
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1083ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
🔄mRNA-1273.211ModernaPhase 3
🔄mRNA-1273ModernaPhase 3
✅mRNA-1273 Variant-containing FormulationModernaApproved

Clinical Trials (1)

NCT IDPhaseStatus
NCT05933304PreclinicalCompleted

Competing Products

20 competing products in SARS-CoV-2, COVID-19

See all competitors
ProductCompanyStageHype Score
mRNA-1010ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1273ModernaPhase 1
0
mRNA-1283ModernaPhase 1
0
mRNA-1273ModernaPreclinical
0
mRNA-1083 Composition 1 Dose A Lot AModernaPhase 2
0
mRNA-1273.214ModernaPhase 2
0
SPIKEVAXModernaPreclinical
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1083.1ModernaPhase 2
0
SPIKEVAX BivalentModernaPreclinical
0
mRNA-1083ModernaPhase 3
0
mRNA-1273ModernaPhase 2
0
mRNA-1073ModernaPhase 2
0
mRNA-1273ModernaPhase 3
0
mRNA-1273ModernaPreclinical
0
mRNA-1273.211ModernaPhase 3
0
mRNA-1083ModernaPhase 2
0